In Vivo Study

1. Tumor volume growth in the F25-treated group was significantly lower than that in the control group, demonstrating its inhibitory effect on tumor growth.

2. F25 significantly reduced tumor weight, demonstrating a significant anticancer effect compared with the control group.

3. The body weight of F25-treated mice remained stable with no significant difference compared to the control group, indicating that F25 is less toxic and better tolerated. This is in contrast to the higher toxicity of the CB-1-treated group (which showed a significant

   decrease in body weight).

​

Thus, F25 exhibited potent antitumor activity with relatively low toxicity in the murine TNBC model, further supporting its value as a potential anticancer drug.